Share chart NeuroPace, Inc.
Extended chart
Simple chart
About NeuroPace, Inc.
NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. The company's RNS system also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip leads and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. more detailsMain settings
IPO date
2021-04-22
ISIN
US6412881053
Industry
Health Care Equipment & Supplies
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Сайт
Grade
Underestimation
| Title | Value | Grade |
| P/S | 4.08 | 4 |
| P/BV | 40.67 | 1 |
| P/E | 0 | 0 |
Efficiency
| Title | Value | Grade |
| ROA | -26.83 | 0 |
| ROE | -189.35 | 0 |
| ROIC | 0 | 0 |
Dividends
| Title | Value | Grade |
| Dividend yield | 0 | 0 |
| DSI | 0 | 0 |
| Average dividend growth | 0 | 0 |
Debt
| Title | Value | Grade |
| Debt/EBITDA | -4.42 | 10 |
| Debt/Ratio | 0.7749 | 9 |
| Debt/Equity | 10.81 | 0 |
Growth impulse
| Title | Value | Grade |
| Yield Revenue, % | 94.42 | 9 |
| Yield Ebitda, % | 32.59 | 5 |
| Yield EPS, % | -71.24 | 0 |
Prices
| Price | Min. | Max. | Change | Changes in the industry | Changes in the index | |
| Yesterday | 11.07 $ | 0 $ | 0 $ | 0 % | 0 % | 0 % |
| Week | 11.83 $ | 11.07 $ | 12.94 $ | -6.42 % | 0 % | 0 % |
| Month | 17.68 $ | 11.07 $ | 18.13 $ | -37.39 % | 0 % | 0 % |
| Three month | 10.42 $ | 10.34 $ | 18.13 $ | 6.24 % | 0 % | 0 % |
| Half a year | 13.12 $ | 10.04 $ | 18.13 $ | -15.63 % | 0 % | 0 % |
| Year | 7.71 $ | 5.9 $ | 18.13 $ | 43.58 % | 0 % | 0 % |
| 3 years | 4.25 $ | 1.29 $ | 18.13 $ | 160.47 % | 0 % | 0 % |
| 5 years | 0 $ | 1.29 $ | 26.5 $ | 0 % | 0 % | 0 % |
| 10 years | 0 $ | 1.29 $ | 26.5 $ | 0 % | 0 % | 0 % |
| Year to date | 12.31 $ | 10.04 $ | 18.13 $ | -10.07 % | 0 % | 0 % |
Main owners
| Institutions | Volume | Share, % |
| KCK Limited | 5 621 111 | 21.39 |
| Orbimed Advisors LLC. | 4 003 967 | 15.23 |
| Morgan Stanley | 2 460 716 | 9.36 |
| Soleus Capital Management, L.P. | 2 433 168 | 9.26 |
| Nantahala Capital Management, LLC | 2 347 354 | 8.93 |
| Kent Lake Capital, LLC | 670 946 | 2.55 |
| FMR, LLC | 468 081 | 1.78 |
| Vanguard Group Inc | 413 106 | 1.57 |
| Millennium Management LLC | 172 403 | 0.66 |
| Geode Capital Management, LLC | 115 996 | 0.44 |
Similar companies
P/E & P/BV
Company management
| Head | Job title | Payment | Year of birth |
| Dr. Martha J. Morrell | Chief Medical Officer | 728.68k | 1957 (68 years) |
| Mr. Joel D. Becker | CEO, President & Director | 762k | 1968 (57 years) |
| Ms. Rebecca L. Kuhn | CFO, VP of Finance & Administration, Corporate Secretary and Assistant Secretary | 614.91k | 1961 (64 years) |
| Ms. Kelley Nicholas | Vice President of Sales | N/A | |
| Ms. Leah Akin | Acting General Counsel | N/A | |
| Mr. Dylan St. John | Chief of Operations & Development |
About company
Address: United States, Mountain View. CA, 455 North Bernardo Avenue - Open in google maps, Open in yandex maps
Website: https://www.neuropace.com
Website: https://www.neuropace.com
